转移性去势抵抗性前列腺癌患者病程中的治疗序贯选择
本文对关键临床试验和近期指南中转移性去势抵抗性前列腺癌(mCRPC)的治疗证据进行综合综述,指出后续治疗选择需考虑个人治疗史、临床特征、症状、预后及临床试验可及性等因素,基因检测和前列腺特异性膜抗原靶向影像有助于评估新型治疗候选资格,并基于个体因素提供治疗序贯建议。
要点
- mCRPC后续治疗选择需综合个人治疗史、临床特征、症状、预后及临床试验可及性。
- 基因检测和PSMA靶向影像用于评估PARP抑制剂及[177Lu]Lu-PSMA-617等新疗法的候选资格。
- 本文基于个体患者因素提供最佳治疗序贯建议。
核心结论
- 本文概述了mCRPC不断演变的治疗格局,讨论指南推荐的治疗选项和关键临床试验数据,并强调可能影响未来治疗格局的正在进行的试验,基于个体患者因素提供最佳治疗序贯建议。
研究设计与样本
- 对已发表的 pivotal 临床试验证据和近期mCRPC治疗指南进行综合综述。
主要发现
- 指导mCRPC治疗选择的关键考虑因素包括个人治疗史、个体临床特征、症状、预后、临床试验可及性及其他患者特异性因素。
- 基因检测和前列腺特异性膜抗原靶向影像学是评估聚(ADP-核糖)聚合酶抑制剂单药或联合雄激素受体通路抑制剂以及[177Lu]Lu-PSMA-617等较新治疗选项候选资格的重要工具。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel therapies for metastatic castration-resistant prostate cancer (mCRPC) have improved patient outcomes. However, there is uncertainty on the optimal selection of therapeutic agents for subsequent lines of therapy. METHODS: We conducted a comprehensive review of published evidence from pivotal clinical trials and recent guidelines for the treatment of mCRPC. We further identify gaps in knowledge and areas for future research. RESULTS: Key considerations to help guide treatment selection for patients with mCRPC include personal treatment history, individual clinical characteristics, symptoms, prognosis, availability of clinical trials, and other patient-specific factors. Genetic testing and prostate-specific membrane antigen-targeted imaging are important tools to evaluate candidacy for newer therapeutic options such as poly (ADP-ribose) polymerase inhibitors, alone or in combination with androgen receptor pathway inhibitors, and [177Lu]Lu-PSMA-617. CONCLUSION: This article provides an overview of the evolving treatment landscape of mCRPC, discussing guideline-recommended treatment options and data from key clinical trials, while highlighting ongoing trials that may impact the future treatment landscape. Recommendations for optimal treatment sequencing based on individual patient factors are provided.
引用
- McManus HD, Dorff T, Morgans AK, et al. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. 2024. PMID: 39420184. doi:10.1038/s41391-024-00906-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。